Information letter addressed to healthcare specialists “DIMETHYL FUMARATE, modified-release capsules 120 mg, important information on minimizing the risk of progressive multifocal leukoencephalopathy (PML) in patients with mild lymphopenia when using dimethyl fumarate”

19.12.2024 629 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я «ДИМЕТИЛ ФУМАРАТ, капсули з модифікованим вивільненням 120 мг, важлива інформація з мінімізації ризику виникнення прогресуючої мультифокальної лейкоенцефалопатії (ПМЛ) у пацієнтів з легкою лімфопенією при застосуванні диметилфумарату»PDF · 164 КБ

Завантажити

Information letter addressed to healthcare specialists “DIMETHYL FUMARATE, modified-release capsules 120 mg, important information on minimizing the risk of progressive multifocal leukoencephalopathy (PML) in patients with mild lymphopenia when using dimethyl fumarate”

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter addressed to healthcare specialists “DIMETHYL FUMARATE, modified-release capsules 120 mg, important information on minimizing the risk of progressive multifocal leukoencephalopathy (PML) in patients with mild lymphopenia when using dimethyl fumarate”

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration